Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 45

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 45
---

the maintenance requirements for continued listing of our common stock, our common stock may be delisted. In the past, we have received
letters from Nasdaq notifying us that we were not in compliance with the $1.00 minimum bid price requirement for continued listing on
Nasdaq under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Although we have complied with the Bid Price Rule as of
the date of this prospectus, there can be no assurance that we will maintain compliance with the Bid Price Rule or any other applicable
Listing Rules of Nasdaq. Nasdaq could issue us another letter notifying us of our non-compliance if our shares of common stock trade less
than $1.00 per share for 30 consecutive business days, and in that event, subsequently make a determination to delist our common stock
if we fail to take appropriate action.

Nasdaq requires us to have, among other requirements, including the
Bid Price Rule, a minimum amount of shareholders’ equity of $2.5 million in order to maintain our listing. Currently, our as adjusted
shareholders’ equity is $4,028,889 as of March 31, 2025. A delisting of our common stock from Nasdaq may materially impair our stockholders’
ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market
for, our common stock. In addition, the delisting of our common stock could significantly impair our ability to raise capital. Also,
our Board may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing.
An active trading market for our shares may never develop or be sustained.

<div align='center'>23</div>

Any delisting determination by Nasdaq could seriously
decrease or eliminate the value of an investment in our common stock and other securities linked to our common stock. While a listing
on an over-the-counter exchange could maintain some degree of a market in our common stock, we could face substantial material adverse
consequences, including, but not limited to, the following: limited availability for market quotations for our common stock; reduced liquidity
with respect to and decreased trading prices of our common stock; a determination that shares of our common stock are “penny stock”
under the SEC rules, subjecting brokers trading our common stock to more stringent rules on disclosure and the class of investors to which
the broker may sell